



Living Cell Technologies Limited

ACN: 104 028 042
ASX: LCT
OTCQB: LVCLY

ASX ANNOUNCEMENT

Appointment of Mr Madhukar Bhalla as Company Secretary

Sydney, Australia & Auckland, New Zealand – 05 December 2022 – Living Cell Technologies (ASX: LCT) (OTCQB: LVCLY) (“LCT” or “the Company”) is pleased to advise that Mr Madhukar “Madhu” Bhalla has been appointed as company secretary to the Company.

Madhu is an experienced company secretary having worked with multiple ASX-listed companies over many years and is proficient in corporate governance, company administration, financial management and corporate law. Madhu is the current company secretary of dual listed biotechnology company, Incannex Healthcare Limited (ASX: IHL) (NASDAQ: IXHL).

The incumbent company secretary, Mark Licciardo of Acclime Australia (‘Acclime’), will cease providing secretarial services to LCT on 26 February 2023. The Board wishes to extend its appreciation to Acclime for their professional support over the past seven years.

Additionally, the Company references the ASX announcement of 31 October 2022 and wishes to advise that Professor Bernie Tuch will cease operating as interim CEO on 28 December 2022, rather than 31 January as previously advised. Finally, LCT advises that 2,400,000 unlisted options will expire on 13 December 2022. The options are held by previous Directors of the Company.

Authorised for release by the Board of Living Cell Technologies Limited.

Ends

For further information: www.lctglobal.com

Corporate and Media Enquiries

Brad Dilkes
Non-executive Director
Mobile: +61 422 180 317
brad@lctglobal.com

About NTCELL

NTCELL is an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells that are sourced from a unique herd of designated pathogen-free pigs bred from stock originally discovered in the remote sub-Antarctic Auckland Islands. Choroid plexus cells are naturally occurring 'support' cells for the brain and secrete cerebrospinal fluid (CSF), which contains a range of factors that support nerve cell functions and protective enzymes that are crucial for nerve growth and healthy functioning. In NTCELL, the porcine choroid plexus cells are coated with alginate to protect them from attack by the immune system. Therefore, no immunosuppressive regimen needs to be administered to recipients.

About Living Cell Technologies

Living Cell Technologies Limited is a biotechnology company focused on discovering and developing novel treatments for debilitating conditions such as diabetes and Parkinson's disease. The Company is incorporated in Australia, with its operations based in Australia and New Zealand. LCT is listed on Australian (ASX: LCT) and US (OTCQB: LVCLY) stock exchanges.

For more information visit www.lctglobal.com or follow @lctglobal on Twitter, Facebook or LinkedIn.

Forward-looking statements

This document may contain certain forward-looking statements, relating to LCT's business, which can be identified by the use of forward-looking terminology such as "promising," "probable", "plans," "anticipated," "will," "project," "believe," "forecast," "expected," "estimated," "targeting," "aiming," "set to," "potential," "seeking to," "goal," "could provide," "intends," "is being developed," "could be," "on track," or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates, nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialisation of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialise, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. LCT is providing this information and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.